Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer

Nakashima, Kazuhisa; Hata, Kojiro; Hotta, Tomomitsu; Tanaka, Satoru; Mitarai, Yuki; Okuno, Takae; Tanino, Akari; Nakao, Mika; Amano, Yoshimasa; Hamaguchi, Megumi; Okimoto, Tamio; Hamaguchi, Shunichi; Nagao, Taishi; Kurimoto, Noriaki; Isobe, Takeshi; Tsubata, Yukari

doi:10.2152/jmi.68.260

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The weakness of this work is that it does not conduct a subgroup analysis of shortened values, which may contribute to an increase in research bias. (2) Responses to immunotherapy might vary depending on the molecular profile of nonsmall-cell lung cancer [40].…”

Section: Discussionmentioning

confidence: 99%

[Retracted] Clinical Efficacy and Safety Analysis of PD‐1/PD‐L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Systematic Review and Meta‐Analysis

Guo

Zhang

Wang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. To systematically evaluate the efficacy and safety of pembrolizumab (PD-1/PD-L inhibitor) and adjuvant chemotherapy to treat NSCLC and provide evidence-based reference for clinical use. Methods. By searching the Cochrane Library, EMBASE, PubMed, and Web of Science, according to the inclusion criteria, literature selection, data extraction, and quality evaluation were carried out for the included literature. The I2 test was used to evaluate heterogeneity between studies, and the meta-analysis was performed using RevMan 5.3 software provided by Cochrane. Results. Finally, 14 relevant documents meeting the standards were included. It is a statistical difference in one-year survival rate [ OR = 1.50 , 95% CI (1.28, 1.76), P < 0.00001 , I 2 = 0 %, Z = 4.99 ]; overall response rate[OR =1.57, 95% CI (1.29, 1.90), P < 0.00001 , I 2 = 0 %, Z = 4.58 ]; progression-free survival [ OR = 2.99 , 95% CI (2.29, 3.91), P < 0.00001 , I 2 = 26 %, Z = 8.00 ]; and overall survival [ OR = 1.38 , 95% CI (1.07, 1.78), P = 0.01 , I 2 = 46 %, Z = 2.50 ] and reduces the incidence of adverse drug reactions [ OR = 2.54 , 95% CI (1.99, 3.25), P < 0.00001 , I 2 = 69 %, Z = 7.43 ]. Conclusion. Pembrolizumab adjuvant chemotherapy is effective in the treatment of advanced NSCLC, but attention should be paid to the occurrence of adverse reactions in clinical. Due to the limitations of the methodology included in the study, this conclusion required more validation of large-sample RCT.

show abstract

Section: Discussionmentioning

confidence: 99%

[Retracted] Clinical Efficacy and Safety Analysis of PD‐1/PD‐L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Systematic Review and Meta‐Analysis

Guo

Zhang

Wang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Inflammation and high nutritional risk have both been associated with low albumin [24]. During an inflammatory process, C-reactive protein (CRP) tends to rise, while albumin levels are noted to drop; the Glasgow Prognostic Score -a combination of CRP and Albumin -has been used in more than 60 studies to predict various outcomes in cancer including survival and chemotherapy effectiveness and tolerability [25][26][27]. As such, albumin levels are a well-established indicator for prognosis in various cancers [28][29][30][31].…”

Section: What Is Halp?mentioning

confidence: 99%

What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types

et al. 2023

View full text Add to dashboard Cite

Since its inception, the Hemoglobin, Albumin, Lymphocyte, Platelet Score (HALP) has gained attention as a new prognostic biomarker to predict several clinical outcomes in a multitude of cancers. In our review, we searched PubMed for articles between the first paper on HALP in 2015 through September 2022, yielding 32 studies in total that evaluated HALP's association with various cancers, including Gastric, Colorectal, Bladder, Prostate, Kidney, Esophageal, Pharyngeal, Lung, Breast, and Cervical cancers, among others. This review highlights the collective association HALP has with demographic factors such as age and sex in addition to TNM staging, grade, and tumor size. Furthermore, this review summarizes HALP's prognostic ability to predict overall survival, progression-free survival, recurrence-free survival, among other outcomes. In some studies, HALP has also been able to predict response to immunotherapy and chemotherapy. This review article also aims to serve as a comprehensive and encyclopedic report on the literature that has evaluated HALP as a biomarker in various cancers, highlighting the heterogeneity surrounding HALP's utilization. Because HALP requires only a complete blood count and albumin - already routinely collected for cancer patients - HALP shows potential as a cost-effective biomarker to aid clinicians in improving outcomes for immuno-nutritionally deficient patients.

show abstract

Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer

Cited by 2 publications

References 18 publications

[Retracted] Clinical Efficacy and Safety Analysis of PD‐1/PD‐L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Systematic Review and Meta‐Analysis

[Retracted] Clinical Efficacy and Safety Analysis of PD‐1/PD‐L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Systematic Review and Meta‐Analysis

What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types

Contact Info

Product

Resources

About